Pfizer expects sales of the Covid vaccine to reach $36 billion in 2021

The American pharmaceutical group Pfizer raised again, its annual sales forecast for its vaccine against Covid-19, supported by recommendations to give a third dose in some countries and the expected licenses for the children's version.

At the beginning of the year, Pfizer expected sales of $15 billion, then raised the figure to 26 billion in May and then 33.5 billion in July

. 2022,” it currently expects to distribute 1.7 billion doses next year, for $29 billion. He stressed, however, that forecasts will be updated based on requests, stressing that sales of vaccines will remain an important source of revenue after 2022.

Pfizer CEO Albert Borla said that the profit-sharing Pfizer and Biontech have so far produced 2.6 billion doses. He noted that planning is underway to produce a total of 3 billion doses this year, including at least 1 billion doses for low- and middle-income countries.

The group is still outperforming its competitors after its vaccine market share in the United States increased from 56% in April to 74% at the end of October, and in the European Union from 70% to 80%.

Burla added that this progress is mainly related to the fact that Kommernati is the first anti-Covid vaccine to obtain emergency permission for a third dose and that “some countries prefer our two-dose vaccine for the youngest.”

At the end of October, the US Food and Drug Administration allowed children aged 5 to 11 to be vaccinated with the Kommernati vaccine.

Follow our latest local and sports news and the latest political and economic developments via Google news